Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2025-04-06
Based on 1102 first isolates · ED · Febrile UTI / pyelonephritis · 2024-04-07 → 2025-04-06
Emergency department
Per-organism detail: ED urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
piperacillin-tazobactam 82 % (79 %–84 %)
Keep for severe or hospital-onset infections.
Not covered: Enterococcus faecalis (9 %), Staphylococcus aureus (3 %), Staphylococcus saprophyticus (2 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
85 %
85 %
n = 79
nitrofurantoin NIT
trend · Escherichia coli not for this site
84 %
85 %
n = 79
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
82 %
84 %
n = 79
ciprofloxacin CIP
trend · Escherichia coli
80 %
80 %
n = 79
mecillinam MEC
trend · Escherichia coli not for this site
79 %
80 %
n = 79
ceftriaxone CRO
trend · Escherichia coli
78 %
82 %
n = 79
trimethoprim TMP
trend · Escherichia coli not for this site
75 %
80 %
n = 79
74 %
82 %
n = 79
53 %
65 %
n = 79
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
12 %
13 %
n = 79
5 %
3 %
n = 79
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
3 %
1 %
n = 79

Most likely organisms for this profile

Escherichia coli
55 %
Klebsiella pneumoniae
11 %
Enterococcus faecalis
9 %
Proteus mirabilis
8 %
Pseudomonas aeruginosa
5 %
Klebsiella oxytoca
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.